Table 1.
Comparison between the three studied groups according to demographic and laboratory data.
| Group I (n = 47) | Group II (n = 54) | Group III (n = 47) | Test of Sig. | p | Sig. Bet. Grps. I vs II I vs III II vs III |
|||
|---|---|---|---|---|---|---|---|---|
| Sex | ||||||||
| Male | 31 (66%) | 32 (59.3%) | 32 (68.1%) | χ2= 0.945 |
0.623 | – | – | – |
| Female | 16 (34%) | 22 (40.7%) | 15 (31.9%) | |||||
| Age (years) | ||||||||
| Mean ± SD. | 60.9 ± 7.9 | 60.5 ± 6.3 | 57.6 ± 8.3 | F= 2.822 |
0.063 | – | – | – |
| Median (Min. – Max.) | 60 (44–79) | 60.5 (49–73) | 58 (36–75) | |||||
| BMI (kg/m2) | ||||||||
| Mean ± SD. | 23.9 ± 4.9 | 26.5 ± 5.1 | 21.5 ± 1.9 | F= 17.550* |
<0.001* | 0.007* | 0.019* | <0.001* |
| Median (Min. – Max) | 23.2 (17.7–31) | 27.23 (18.6–38) | 21.6 (18.6–24.6) | |||||
| TLC (103/mm3) | ||||||||
| Mean ± SD | 7.9 ± 1.3 | 7.7 ± 1.2 | 7.3 ± 1.3 | F = 2.963 | 0.055 | – | – | – |
| Median (Min. – Max.) | 8 (4.9–10.1) | 8.1 (4.9–9.7) | 7.6 (4.9–9.8) | |||||
| Hb(gm/dl) | ||||||||
| Mean ± SD | 10.3 ± 2.1 | 10 ± 1.7 | 13.9 ± 1.2 | F= 77.734* |
<0.001* | 0.478 | <0.001* | <0.001* |
| Median (Min. – Max) | 10.4 (5.5–15) | 9.7 (4.5–14.2) | 13.8 (11.8–16.1) | |||||
| Platelets (103/mm3) | ||||||||
| Mean ± SD | 294.2 ± 75.1 | 258.4 ± 79.1 | 255.5 ± 71.2 | F= 3.924* |
0.022* | 0.048* | 0.036* | 0.979 |
| Median (Min. – Max.) | 289 (165–420) | 276 (155–421) | 258 (164–421) | |||||
| Albumin (g/dl) | ||||||||
| Mean ± SD. | 3.9 ± 0.3 | 4 ± 0.3 | 4 ± 0.5 | F = 1.841 | 0.162 | – | – | – |
| Median (Min. – Max). | 3.8 (3.5–4.3) | 3.9 (3.7–4.9) | 3.9 (3.5–5.7) | |||||
| Total bilirubin (mg/dl) | ||||||||
| Mean ± SD | 1 ± 0.2 | 1 ± 0.2 | 1 ± 0.2 | F = 0.107 | 0.898 | – | – | – |
| Median (Min. – Max.) | 0.9 (0.6–1.4) | 1 (0.6–1.3) | 1 (0.6–1.3) | |||||
| ALT (U/L) | ||||||||
| Mean ± SD | 29.2 ± 9 | 28.4 ± 6.9 | 25.8 ± 6.1 | F = 2.804 | 0.064 | – | – | – |
| Median (Min. – Max) | 31 (17–56) | 29 (18–50) | 27 (17–38) | |||||
| AST (U/L) | ||||||||
| Mean ± SD. | 27.6 ± 5.5 | 26.9 ± 5.8 | 256 ± 5.9 | F = 2.494 | 0.086 | – | – | – |
| Median (Min. – Max.) | 28 (18–37) | 28 (18–35) | 27 (14–35) | |||||
| H. pylori | ||||||||
| No | 37 (78.7%) | 20 (37%) | 47 (100%) | χ2= 50.040* |
<0.001* | <0.001* | 0.001* | <0.001* |
| Yes | 10 (21.3%) | 34 (63%) | 0 (0%) | |||||
| CEA (U/ml) | ||||||||
| Mean ± SD | 56.91 ± 97.8 | 9.34 ± 7.40 | 6.38 ± 5.4 | H= 30.439* |
<0.001* | <0.001* | <0.001* | 0.055 |
| Median (Min. – Max) | 14.90 (3–575) | 5.10 (1.10–22) | 3.40 (0.80–13) | |||||
| CA19–9(U/ml) | ||||||||
| Mean ± SD | 54.91 ± 31.9 | 15.43 ± 8.67 | 13.36 ± 7.4 | H= 48.108* |
<0.001* | <0.001* | <0.001* | 0.353 |
| Median (Min. – Max.) | 54 (7.5–112) | 16 (1–37) | 12 (2–29) | |||||
| ESR | ||||||||
| Mean ± SD | 709 ± 32.17 | 10.81 ± 2.67 | 10.30 ± 2.96 | H= 87.755* |
<0.001* | <0.001* | <0.001* | 0.452 |
| Median (Min. – Max.) | 78 (10–110) | 11 (6–15) | 10 (5–17) | |||||
| miR-30a-5p | ||||||||
| Mean ± SD | 2.21 ± 0.83 | 7.96 ± 4.91 | 9.50 ± 4.45 | H= 84.210* |
<0.001* | <0.001* | <0.001* | 0.157 |
| Median (Min. – Max.) | 2.37 (0.05–3.50) | 6.17 (2.5–20) | 9.50 (2.7–25.7) | |||||
| miR-182-5p | ||||||||
| Mean ± SD. | 2.67 ± 1.26 | 7.98 ± 3.51 | 9.36 ± 4.90 | H= 65.801* |
<0.001* | <0.001* | <0.001* | 0.368 |
| Median (Min. – Max.) | 2.91 (0.1–4) | 8.13 (2–17) | 8.10 (2.4–20.9) | |||||
BMI: Body Mass Index, Hb: Hemoglobin concentration, TLC; Total Leukocyte Count, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, CEA; Carcinoembryonic Antigen, CA19-9; Carbohydrate Antigen 19–9, ESR: Erythrocyte Sedimentation Rate, χ2: Chi-square test, F: F for ANOVA test, Pairwise comparison bet. The two groups were done using a post hoc test (Tukey), H: H for the Kruskal Wallis test, pairwise comparison bet. The two groups were done using a post hoc test (Dunn's for multiple comparisons test), P: P-value for comparing between the studied groups.
*: Statistically significant at p < 0.05, IQR: Inter Quartile Range.
Group I: Gastric cancer Group II: Benign gastric lesion Group III: Control.